Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market

Executive Summary

The FDA's rejection of Sandoz Inc.'s version of Amgen's Neulasta (pegfilgrastim) has revealed the hard truth that chasing the biosimilar market may be a riskier and more costly endeavor than companies anticipated.


Related Content

Sandoz Sanguine On Market Opportunity Despite Biosimilar Neulasta Setback
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Does Novartis Need A Big Immuno-Oncology Deal? Jimenez Says No
Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Tentative-Style Approvals Coming For US Biosimilars?
Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts
1st U.S. Biosimilar Arrives: Zarxio Launches; Legal Saga Ongoing
Novartis/Sandoz make history with 1st US biosimilar Zarxio
Apotex 2nd biosimilar under FDA review; seeks filgrastim OK
Apotex biosimilar of Amgen's Neulasta under FDA review


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts